EPSRC Centre for Doctoral Training in Bioprocess Engineering Leadership (Complex Biological Products Manufacture)

英国政府对生命科学产业战略(Bell Report，2017)的支持认识到开发新药对促进英国经济增长的重要性。例如，治疗癌症的新抗体疗法，控制传染病传播的新疫苗，以及治愈失明和痴呆症等以前无法治愈的疾病的细胞和基因疗法的出现。生物处理技术为这种下一代复杂生物制品的安全、成本效益和环境友好型制造奠定了基础。它们促进了将生命科学发现快速转化为新药物，使需要它们的患者受益。然而，最近的报告强调了特定的技能短缺，这限制了英国利用这些领域创造财富和就业机会的能力。他们强调，需要“更多接受过先进制造培训的个人”，以及拥有生物处理技能的个人，他们能够应对“使用生物材料扩大生产的挑战”。UCL EPSRC CDT在生物过程工程领导力方面拥有成功的记录，为研究生科学家和工程师配备工业所需的生物处理技能。它将围绕支持药品制造的核心发酵和下游加工技能，提供“全生物过程”培训主题。该方案旨在加速毕业生进入博士研究，并建立一个多学科研究队列；这将通过与爱尔兰合成和固态药物中心(SSPC)和国家生物过程研究和培训研究所(NIBRT)的伙伴关系得到加强。研究项目将与英国和国际领先的公司合作开展。对CDT的持续需求证明了这一事实，即96%的以前的毕业生已经晋升到相关的生物行业职业，其中许多人现在处于高级领导职位。下一代分子或细胞药物将变得越来越复杂，因此很难描述。这意味着它们将更难大规模生产，更难确保它们不仅安全，而且具有成本效益。这项提议将使CDT能够培训未来的生物行业领导者，他们拥有制造这种下一代复杂生物药物所需的理论知识和实践和商业技能。这将通过使每个研究人员与国际领先的研究小组保持一致并制定个人培训和职业发展方案来实现。通过这种方式，CDT将为英国生物工艺使用行业未来的成功做出贡献。

The UK government's support for the Life Sciences Industry Strategy (Bell Report, 2017) recognises the importance of developing new medicines to facilitate UK economic growth. Examples include new antibody therapies for the treatment of cancer, new vaccines to control the spread of infectious diseases and the emergence of cell and gene therapies to cure previously untreatable conditions such as blindness and dementia. Bioprocessing skills underpin the safe, cost-effective and environmentally friendly manufacture of this next generation of complex biological products. They facilitate the rapid translation of life science discoveries into the new medicines that will benefit the patients that need them.Recent reports, however, highlight specific skills shortages that constrain the UK's capacity to capitalise on opportunities for wealth and job creation in these areas. They emphasise the need for 'more individuals trained in advanced manufacturing' and for individuals with bioprocessing skills who can address the 'challenges with scaling-up production using biological materials'.The UCL EPSRC CDT in Bioprocess Engineering Leadership has a successful track record of equipping graduate scientists and engineers with the bioprocessing skills needed by industry. It will deliver a 'whole bioprocess' training theme based around the core fermentation and downstream processing skills underpinning medicines manufacture. The programme is designed to accelerate graduates into doctoral research and to build a multidisciplinary research cohort; this will be enhanced through a partnership with the Synthesis and Solid State Pharmaceutical Centre (SSPC) and the National Institute for Bioprocess Research and Training (NIBRT) in Ireland. Research projects will be carried out in partnership with leading UK and international companies. The continued need for the CDT is evidenced by the fact that 96% of previous graduates have progressed to relevant bioindustry careers and many are now in senior leadership positions.The next generation of molecular or cellular medicines will be increasingly complex and hence difficult to characterise. This means they will be considerably more difficult to manufacture at large scale making it harder to ensure they are not only safe but also cost-effective. This proposal will enable the CDT to train future bioindustry leaders who possess the theoretical knowledge and practical and commercial skills necessary to manufacture this next generation of complex biological medicines. This will be achieved by aligning each researcher with internationally leading research teams and developing individual training and career development programmes. In this way the CDT will contribute to the future success of the UK's bioprocess-using industries.